Successful treatment of AA amyloidosis with tocilizumab, resulting in the disappearance of amyloid deposits: a case-based review

Abstract Background AA amyloidosis is a multisystem disease characterized by the deposition of serum amyloid A protein, which is secondary to chronic inflammation. Tocilizumab (an interleukin-6 inhibitor monoclonal antibody) was effective in suppressing inflammation, normalizing serum amyloid A prot...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Marina Tortosa-Cabañas, José Acosta Batlle, Cristian Perna, Javier Bachiller-Corral
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	SpringerOpen 2024-09-01
Saila:	Egyptian Rheumatology and Rehabilitation
Gaiak:	Amyloid A amyloidosis Serum amyloid A protein Nephrotic syndrome Oligoarthritis IL-6 inhibitor Tocilizumab
Sarrera elektronikoa:	https://doi.org/10.1186/s43166-024-00281-6
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!